Financial News

bluebird bio, Inc. Reports Inducement Grants to CCO Tom Klima Under Nasdaq Listing Rule 5635(c)(4)

Products You May Like

Article content material

CAMBRIDGE, Mass. — bluebird bio, Inc. (Nasdaq: BLUE) at the moment introduced that the Compensation Committee of the Firm’s Board of Administrators accepted inducement grants of inventory choices to buy a complete of fifty,000 shares of widespread inventory and 25,000 restricted inventory items (“RSUs”) to its Chief Industrial Officer Tom Klima with a grant date of June 1, 2021 (the “Inducement Grants”).

The inventory choices accepted beneath the Inducement Grants have an train value per share equal to $31.11, the honest market worth on the grant date. The inventory choices vest over 4 years, with 25% vesting on the one-year anniversary of Mr. Klima’s first day of employment with the Firm and 1/36 of the remaining shares vesting month-to-month thereafter, topic to Mr. Klima’s continued service with the Firm on every such date. The inventory choices have a 10-year time period and are topic to the phrases and circumstances of the inventory choice settlement.

The RSUs accepted beneath the Inducement Grants vest over 4 years, 25% on the primary anniversary of the date of grant and in three equal annual installments for the next three years on the anniversaries of the date of grant.

The Firm granted the inventory choices and RSUs as inducement supplies to Tom Klima getting into into employment with bluebird bio, Inc. in accordance with NASDAQ Itemizing Rule 5635(c)(4).

Article content material

About bluebird bio, Inc.

bluebird bio, Inc. (NASDAQ: BLUE) is bluebird bio is pioneering gene remedy with function. From our Cambridge, Mass., headquarters, we’re growing gene and cell therapies for extreme genetic illnesses and most cancers, with the objective that individuals dealing with probably deadly circumstances with restricted therapy choices can stay their lives absolutely. Past our labs, we’re working to positively disrupt the healthcare system to create entry, transparency and training in order that gene remedy can turn out to be out there to all those that can profit.

bluebird bio is a human firm powered by human tales. We’re placing our care and experience to work throughout a spectrum of problems together with cerebral adrenoleukodystrophy, sickle cell illness, β-thalassemia and a number of myeloma utilizing three gene remedy applied sciences: gene addition, cell remedy and (megaTAL-enabled) gene enhancing.

bluebird bio has extra nests in Seattle, Wash.; Durham, N.C.; and Zug, Switzerland. For extra info, go to

Comply with bluebird bio on social media: @bluebirdbio, LinkedIn, Instagram and YouTube.

bluebird bio is a trademark of bluebird bio, Inc.

Cautionary Observe on Ahead-Wanting Statements

This press launch consists of forward-looking statements pertaining to the continued service of an worker and future vesting of inducement grants in addition to to our enterprise and operations, together with the invention, improvement, and commercialization of our product candidates. Such forward-looking statements will be assured. Ahead-looking statements on this press launch ought to be evaluated along with the numerous dangers and uncertainties that have an effect on bluebird bio’s enterprise, notably these recognized within the threat components dialogue in bluebird bio’s Annual Report on Kind 10-Okay, as up to date by our subsequent Quarterly Stories on Kind 10-Q, Present Stories on Kind 8-Okay and different filings with the Securities and Trade Fee. The forward-looking statements included on this doc are made solely as of the date of this doc and besides as in any other case required by relevant regulation, bluebird bio undertakes no obligation to publicly replace or revise any forward-looking assertion, whether or not on account of new info, future occasions, modified circumstances or in any other case.

View supply model on



Buyers & Media

Elizabeth Pingpank, 617-914-8736

Jenn Snyder, 617-448-0281

Products You May Like